Caralluma fimbriata.
An edible Indian succulent taken for appetite. Its pregnane glycosides are what standardised extracts are measured against, and trials tracked reported hunger and waist measurement.
Reviewed March 2026
- Category
- Herb
What Caralluma fimbriata is, and what it does.
- Does it work
- Suits people eating in a deficit who want a plant option for appetite alongside the diet. The literature is small at 83 records and the recorded changes were modest.
- How much to take
- Start with 500mg a day of standardised extract and settle anywhere up to 1,000mg. That band is where the appetite work sits, often split into two doses.
- Time to feel it
- Where appetite effects show up, people report them inside the first two weeks. Trials tracked intake and waist measures over 30 to 60 days.
- The first dose
- Day one is usually quiet. Some people find they finish a meal sooner; for others the first days pass without a sensation they'd put a name to.
- With regular use
- Across eight to twelve weeks, trials followed reported appetite and waist measurement. The changes recorded were small and steady rather than dramatic.
- How well tolerated
- Well tolerated in the trials on record, with mild digestive upset the usual report. Check with your clinician if you're pregnant, breastfeeding or on medication.
- How it feels
- Quiet. Some people find they finish meals sooner or reach less between them, and for others the difference shows up in what they eat rather than in a sensation.
- The overlooked benefit
- It's a vegetable before it's a capsule. The stems are cooked and eaten in parts of India, so there's a long food history sitting behind the extract.
500 to 1,000mg a day is where Caralluma fimbriata works.
Source: Kuriyan et al. (2007) Appetite; Griggs et al. (2015) Complement Ther Med
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Caralluma fimbriata has emerging evidence. Based on 83+ studies.
- reported appetite and food intakeRandomised trial
- waist measurement over eight to twelve weeksRandomised trial
- body composition during a weight-loss phaseNarrative review
- pregnane glycoside content as the standardisation markerNarrative review
Questions people ask about Caralluma fimbriata.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Glucomannan swells in gastric fluid and slows gastric emptying, which is a physical route to fullness. Caralluma extract is used for appetite behaviour through a different, centrally proposed route. The two act on separate steps of the same sensation, so formulators combine them. No trial has measured the pair together, so read this as mechanistic rather than clinical.
Psyllium forms a gel that increases meal viscosity and slows nutrient delivery to the small intestine. Caralluma is taken before meals for the same end point, satiety, by a different mechanism. The pairing is formulation convention in satiety blends. Fibre also blunts absorption of some co-ingested actives, so spacing matters.
Chromium participates in normal insulin signalling and is a routine component of blends aimed at glucose handling. Caralluma extract has been examined for metabolic risk markers in small human work. Both touch glycaemic markers rather than clinical outcomes. Anyone already managing blood sugar with medicine should have a clinician review the combination.
Gymnema gymnemic acids blunt sweet taste perception at the tongue for a period after dosing. Caralluma is used before meals in the same tradition for hunger. The overlap is behavioural rather than biochemical. No combination trial exists, so the pairing is traditional practice.
Green tea catechins act on catecholamine turnover and energy expenditure. Caralluma acts on the intake side of the same balance. They are stacked in weight-management products for that reason. Concentrated catechin extracts carry their own dosing cautions, so the pair is not a free addition.
Caffeine antagonises adenosine receptors and raises resting energy expenditure modestly. Caralluma is used on the intake side. Together they are a common commercial pairing rather than a studied one. Caffeine also blunts hunger on its own, which makes attributing any effect to either component difficult.
Berberine activates AMPK and has been examined for fasting glucose and lipid markers. Caralluma extract has been examined for similar markers in small human and animal work. Stacking two agents that both move glycaemic markers can produce more effect than either alone. Markers are not outcomes, and this combination has not been measured together.
Inulin is fermented in the colon to short-chain fatty acids, which signal through gut peptides tied to fullness. Caralluma is used for the same sensation by a proposed hypothalamic route. The two are separate steps rather than one shared pathway. Fermentable fibre can cause gas at higher doses, which limits how much can be stacked.
Carnitine carries long-chain fatty acids across the inner mitochondrial membrane, an established transport step. Caralluma sits on the appetite side rather than the oxidation side. The pairing is a formulation choice covering two different points of energy balance. No combination data exists.
Nothing specific on file for Caralluma fimbriata. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Caralluma fimbriata actually does.
Caralluma fimbriata is an edible succulent in the Apocynaceae family, and its characterised compounds are pregnane glycosides alongside megastigmane and flavone glycosides. Standardised extracts are measured against that pregnane glycoside fraction.
Pregnane glycosides are big steroid molecules with sugars hung off them. Molecules that size and polarity don't cross the gut wall intact. Gut bacteria and intestinal enzymes strip the sugars off well before anything reaches your bloodstream.
Where Caralluma fimbriata comes from.
It comes from a cactus-like plant eaten as a vegetable in parts of India. The stems are boiled down into a concentrated liquid, checked for how much of the active plant compound it holds, then dried into a powder for capsules.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
Caralluma fimbriata is a cactus-like succulent of arid India, eaten as a vegetable and grown for supply in Andhra Pradesh and neighbouring states. The aerial stems are the part collected.
Washed, chopped stems are extracted in water, or in an ethanol and water mixture, to draw the pregnane and flavone glycosides out of the plant tissue.
Solids are filtered off and the liquor is concentrated under reduced pressure, which lowers the temperature needed and limits thermal loss of the glycosides.
The concentrate is assayed by chromatography and blended to a declared pregnane glycoside percentage, which is the number that appears on the label.
The standardised concentrate is spray dried onto a carrier such as maltodextrin and encapsulated or tableted.
Getting Caralluma fimbriata from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Pooling randomised trials of Caralluma fimbriata extract in adults with excess body weight, the review reported small reductions in waist circumference and self-rated appetite, while body weight differences versus placebo were inconsistent across trials.Meta-analysis. Jayawardena et al., 2021 (BMC complementary medicine and therapies). PMID 34758791 ↗
- In adults with excess body weight taking an oral Caralluma fimbriata extract, the trial reported reductions in waist measurements and self-rated appetite compared with placebo, with body weight largely unchanged.Randomised trial. Rao et al., 2021 (Scientific reports). PMID 33762661 ↗
- Reviewing plant compounds studied for appetite and satiety, the authors placed Caralluma fimbriata among the few with human trial data for lower hunger ratings, and described the size of the effect as small and variable between studies.Systematic review. Stuby et al., 2019 (Nutrients). PMID 31533291 ↗
- A 12-week pilot in overweight adults reported changes in anthropometric and metabolic risk markers with the extract, with the authors noting that pilot size limits what can be concluded.Randomised trial. Astell et al., 2013 (Complementary Therapies in Medicine). PMID 23642949 ↗
- The authors reported lower hyperphagia-related appetite behaviour scores during extract supplementation compared with placebo in a small crossover.Randomised trial. Griggs et al., 2015 (North American Journal of Medical Sciences). PMID 26713299 ↗
- The authors report movement in metabolic risk biomarkers with the edible plant preparation; these are markers measured in blood, not clinical outcomes.Randomised trial. Anwar et al., 2022 (Oxidative Medicine and Cellular Longevity). PMID 35770046 ↗
- In rodents, the authors report antioxidant activity and changes in glucose-handling markers with the extract.Animal study. Arif et al., 2024 (Toxicology Research). PMID 38957782 ↗
- In mice fed a high-fat diet, the authors report improved measures of vascular function with the extract; an animal finding, not human evidence.Animal study. Thunuguntla et al., 2024 (Nutrients). PMID 39770917 ↗
- The authors describe plant tissue culture as a production route for the metabolites of interest, a manufacturing and yield question rather than a human effect.In vitro study. Ali et al., 2022 (Frontiers in Endocrinology). PMID 36601006 ↗
- A review of plants and phytonutrients reported to modulate hypothalamic-pituitary-adrenal axis markers in human studies; the ingredient is named within the broader set rather than being the subject of the review.Systematic review. Lopresti et al., 2022 (Nutritional Neuroscience). PMID 33650944 ↗
These are the studies our verdict leans on, chosen from the 26 we read for Caralluma fimbriata. The full linked list is below.
The studies, linked.
1 source behind our Caralluma fimbriata verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialThe Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters, a Randomised Placebo-controlled Double-blind StudyClinicalTrials.gov ↗PHASE2 · 129 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
